<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873414</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-CT002</org_study_id>
    <nct_id>NCT04873414</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma as Adjunct Therapy for COVID-19</brief_title>
  <acronym>PlaSenTer</acronym>
  <official_title>Clinical Trial of Convalescent Plasma Administration as Adjunct Therapy for COVID-19 (Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indonesian Red Cross</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eijkman Institute for Molecular Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Convalescent plasma (CP) has been the subject of increasing expectation for treating&#xD;
      coronavirus disease 2019 (COVID-19). Reports on CP transfusion have shown promising clinical&#xD;
      improvements without serious adverse events. To date, most studies focused on reporting CP&#xD;
      treatment in patients with severe COVID-19, but only a few addressed benefits on less severe&#xD;
      disease. The vast majority of studies reporting COVID-19 infection and treatment have come&#xD;
      from earlier affected countries with established health systems and research infrastructure,&#xD;
      while very few are from low- and middle-income countries (LMICs). Nonetheless, CP therapy&#xD;
      could be one of the few available options in LMICs where constraints may exist in the access&#xD;
      to novel treatments, even once available. Clinical trials conducted in LMICs may differ in&#xD;
      many respects from those in high-income countries.&#xD;
&#xD;
      This study will evaluate the safety and efficacy of convalescent plasma therapy in&#xD;
      hospitalized with moderate and severe COVID-19, to investigate the impacts of the treatment&#xD;
      over the course of clinical illness, including non-mortal clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2), has spread rapidly around the world, with high rates of&#xD;
      transmission and substantial mortality.&#xD;
&#xD;
      Convalescent plasma (CP) collected from recovered patients has been evaluated in the&#xD;
      treatment of SARS, Middle East respiratory syndrome (MERS), and Ebola, but not well further&#xD;
      studied and with no definitive results. Preliminary studies in COVID-19 patients showed&#xD;
      improvement in clinical status after CP transfusion. However, a multicenter, open-label,&#xD;
      randomized clinical trial of 103 patients in China with severe or life-threatening COVID-19&#xD;
      found no statistical difference in clinical improvement within 28 days among patients treated&#xD;
      with CP versus standard treatment alone.&#xD;
&#xD;
      To date, CP has not been approved as a standard of care for COVID-19. There are insufficient&#xD;
      data from well-controlled, adequately powered, randomized clinical trials to evaluate the&#xD;
      efficacy and safety of CP for the treatment of this disease. One randomized controlled trial&#xD;
      (NCT04342182) was halted for redesign based on the consideration that most COVID-19 patients&#xD;
      already have high neutralizing antibody titers at hospital admission and no difference in&#xD;
      mortality (p=0.95), hospital stay (p=0.68), or day-15 disease severity (p=0.58) was observed&#xD;
      between plasma treated patients and patients on standard of care. Another clinical study&#xD;
      (NCT04345523) showed efficacy and safety of CP in preventing progression to severe disease or&#xD;
      death. However, this study was halted early due to low enrolment. Further studies have been&#xD;
      published and assessed in several systematic reviews that remain uncertain about the safety&#xD;
      and effectiveness of CP treatment for COVID-19.&#xD;
&#xD;
      The vast majority of studies reporting COVID-19 trials have come from the earlier affected&#xD;
      countries with established healthcare systems and better research infrastructure, while very&#xD;
      few are from low- and middle-income countries (LMICs). Meanwhile, the cases in LMICs have&#xD;
      risen considerably with critical research questions specific to the needs of are hard to&#xD;
      answer. As an LMIC with a geographically dispersed archipelago, access to healthcare remains&#xD;
      a challenge in remote districts that could impact the adoption of CP deployment in Indonesia.&#xD;
      Consequently, clinical trials conducted in LMICs may differ in many respects from those in&#xD;
      high-income countries.&#xD;
&#xD;
      This study will evaluate the safety and efficacy of CP therapy in hospitalized with moderate&#xD;
      and severe COVID-19, to investigate the impacts of the treatment over the course of clinical&#xD;
      illness, including non-mortal clinical outcomes. This study will involve hospitals from&#xD;
      different places of the Indonesian archipelago, with different characteristics and community&#xD;
      structures, social, and values. To obtain supports for the trial, the investigators will seek&#xD;
      community engagement that allows investigators and community leaders working collaboratively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mortality in COVID-19 patients treated with convalescent plasma</measure>
    <time_frame>From the initiation of CP treatment until hospital discharge or death, up to 28 days</time_frame>
    <description>Number of deaths from the initiation of CP treatment until hospital discharge or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status category in CP-receiving patients</measure>
    <time_frame>From the initiation of CP treatment until hospital discharge or death, up to 28 days</time_frame>
    <description>Change in clinical status category will be scored daily based on the modified WHO six-point ordinal scale. The six-point scale is as follows: 1, non-hospitalized; 2, hospitalized, without supplemental oxygen; 3, hospitalized, with supplemental oxygen; 4, hospitalized, with nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 5, hospitalized, with invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO), or both; and 6, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From admisstion until hospital discharge or death, up to 28 days</time_frame>
    <description>Number of days from the admission to the date of discharge or death. Patients who are not discharged and remain in the hospital at the end of study period will be censored on the study's end date, while those who are lost to follow-up will be censored on the last encounter date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>From the initiation of CP treatment until hospital discharge or death, up to 28 days</time_frame>
    <description>Number of days in patients with ventilatory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>From the initiation of CP treatment until hospital discharge or death, up to 28 days</time_frame>
    <description>Number of days from entry to release from ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lung image radiography in CP-receiving patients</measure>
    <time_frame>Days 0, 6, 14, 21, and 28</time_frame>
    <description>The lung radiological image will be assessed using the Brixia chest X-ray scoring (Morghesi and Maroldi, 2020). Each lung is divided into three zones, marked by letters A, B, and C for the right lung, and D, E, and F for the left lung. The letters divide the lungs into three levels: upper level (A and D), above the inferior wall of the aortic arch; middle level (B and E), below the inferior wall of the aortic arch and above the inferior wall of the right inferior pulmonary vein; and lower level (C and F), below the inferior wall of the right inferior pulmonary vein. A score (from 0 to 3) is assigned to each zone based on the detected lung abnormalities: 0, no lung abnormalities; 1, interstitial infiltrates; 2, interstitial and alveolar infiltrates (interstitial pre-dominance); and 3, interstitial and alveolar infiltrates (alveolar predominance). The overall CXR score is the sum of points from the six lung zones with a range from 0 to 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory parameters in CP-receiving patients</measure>
    <time_frame>Days 0, 6, 14, 21, and 28</time_frame>
    <description>Measurement of C-reactive protein (reference: &lt;5.0 mg/L); neutrophil/lymphocyte ratio reference range: male, 0.43~2.75; female,0.37~2.87), procalcitonin (reference: &lt;0.15 ng/mL), and IL-6 (reference range: (5-15 pg/ml) levels in CP-receiving patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation parameters in CP-receiving patients</measure>
    <time_frame>Days 0, 6, 14, 21, and 28</time_frame>
    <description>Measurement of D-Dimer (reference: &lt;0.5 mcg/mL) and prothrombin time (reference range: 11.0-13.6) seconds in CP-receiving patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in viral load in CP-receiving patients</measure>
    <time_frame>Days 0, 3, 6, 14, 21, and 28</time_frame>
    <description>Measurement of viral load by nasopharyngeal swab PCR in CP-receiving patients. Additional test on day 3 will be performed to identify the early clearance of the virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anti-SARS-CoV-2 antibody levels in CP-receiving patients</measure>
    <time_frame>Days 0, 3, 6, 14, 21, and 28</time_frame>
    <description>Plasma/serum titer of anti-SARS-CoV-2 antibodies in CP-receiving patients by the plaque reduction neutralization test or enzyme-linked immunosorbent assay. Additional test on day 3 will be performed to identify the early changes in antibody levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic organ involvement in patients receiving CP treatment</measure>
    <time_frame>Days 0, 6, 14, 21, and 28</time_frame>
    <description>Systemic organ involvement measured by the Sequential Organ Failure Assessment (SOFA) score. It is used for calculation of both the number and the severity of organ dysfunction in six organ systems (respiratory, coagulatory, liver, cardiovascular, renal, and neurologic), and can measure individual or aggregate organ dysfunction. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The SOFA score ranges from 0 to 24. An increasing or unchanged SOFA score is associated with a higher mortality rate than patients with a decreasing score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of symptoms in patients receiving CP treatment</measure>
    <time_frame>Days 0, 6, 14, 21, and 28</time_frame>
    <description>Patients whose symptoms are not resolved and remain in the hospital at the end of study period will be censored on the study's end date, while those are lost to follow-up will be censored on the last encounter date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From the initiation of CP treatment until hospital discharge or death, up to 28 days</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of anti-SARS-CoV-2 antibody levels in donors on the efficacy of CP therapy in CP-receiving patients</measure>
    <time_frame>Days 0, 6, 14, 21, and 28</time_frame>
    <description>Correlation between anti-SARS-CoV-2 antibody levels in donors and the clinical status of CP-receiving patients according to the modified WHO 6-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of anti-SARS-CoV-2 antibody levels in donors on the viral clearance in CP-receiving patients</measure>
    <time_frame>Days 0, 3, 6, 14, 21, and 28</time_frame>
    <description>Correlation between anti-SARS-CoV-2 antibody levels in the donors and the viral clearance in CP-receiving patients. Additional test on day 3 will be performed to identify the early clearance of the virus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">364</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the Treatment Group are given 200 ml of Plasma collected from Convalescent Patients recovered from COVID-19 at two-day intervals in addition to standard supportive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the Control Group are given standard supportive treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma treatment</intervention_name>
    <description>Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Patients with PCR-confirmed COVID-19&#xD;
&#xD;
          2. Minimal age:18 years&#xD;
&#xD;
          3. Agree to participate in the trial with written informed consent&#xD;
&#xD;
          4. Moderate or Severe COVID-19 at the time of enrollment&#xD;
&#xD;
             .&#xD;
&#xD;
             A. Definition of moderate disease (according to Siddiqi et al):&#xD;
&#xD;
             Moderate COVID-19 is defined as disease with fever, respiratory symptoms (dry cough,&#xD;
             chest distress, or shortness of breath after activities), and pulmonary imaging&#xD;
             findings, and at least one of the following findings:&#xD;
&#xD;
             i) Abnormal coagulation parameters:&#xD;
&#xD;
               -  D-dimer &gt;1 µg/mL (normal &lt;0.5 µg/mL)&#xD;
&#xD;
               -  Prothrombin time (&gt;13.6 second) or International normalized ratio (INR) ≥1.8&#xD;
&#xD;
               -  Thrombocyte count &lt;100x 10^3/mL&#xD;
&#xD;
             ii) Increased pro-inflammatory markers:&#xD;
&#xD;
               -  C-reactive protein (CRP) ≥26.9 mg/L&#xD;
&#xD;
               -  Procalcitonin ≥0.5 ng/mL,&#xD;
&#xD;
               -  Lymphocyte count &lt;1.5x 10^9/L) or Neutrophil/Lymphocyte ratio (NLR) &gt;3.3&#xD;
&#xD;
             iii) Presence of risk factors or comorbidities:&#xD;
&#xD;
               -  Age &gt;65 years&#xD;
&#xD;
               -  Type 1 Diabetes Mellitus or type 2 Diabetes Mellitus (with any of the following:&#xD;
                  Fasting blood glucose ≥126 mg/dl, 2-h plasma glucose ≥200 mg/dL, or random plasma&#xD;
                  glucose ≥200 mg/dL, plus HbA1C &gt;6.5%)&#xD;
&#xD;
               -  Chronic kidney disease (creatinine &gt;2.0 mg/dL) or with routine hemodialysis&#xD;
&#xD;
               -  Chronic liver Disease with signs of liver cirrhosis; Child-Turcotte-Pugh (CTP)&#xD;
                  Class A (score 5-6) or Class B (score 7-9) or higher; or Model for End-Stage&#xD;
                  Liver Disease (MELD) score &lt;39&#xD;
&#xD;
               -  Heart failure (New York Health Association [NYHA] Class I or II)&#xD;
&#xD;
               -  Bronchial asthma, chronic obstructive pulmonary disease (COPD), or pulmonary&#xD;
                  tuberculosis&#xD;
&#xD;
               -  Cancer (particularly patients with chemotherapy or immunotherapy)&#xD;
&#xD;
               -  Immunocompromised conditions, including HIV/AIDS, post-organ transplantation, or&#xD;
                  judged by attending physician (preferable after specialist consultation)&#xD;
&#xD;
               -  Long-term corticosteroid use&#xD;
&#xD;
               -  autoimmune disease&#xD;
&#xD;
               -  Sequential Organ Failure Assessment [SOFA] score ≥5.65&#xD;
&#xD;
               -  Body Mass Index (BMI) ≥35 kg/m2&#xD;
&#xD;
             B. Definition of severe COVID-19 (according to Siddiqi et al):&#xD;
&#xD;
             Severe Covid-19 is defined as disease with a respiratory rate ≥30 breaths/min, oxygen&#xD;
             saturation &lt;90% or oxygenation index (PaO2/FiO2) ≤300 mmHg, and/or lung infiltrates&#xD;
             &gt;50% within 24-48 h.&#xD;
&#xD;
             EXCLUSION CRITERIA:&#xD;
&#xD;
               -  Pregnant or lactating woman&#xD;
&#xD;
               -  History of transfusion reaction, blood-group incompatibility, IgA deficiency, or&#xD;
                  Allergy to Immunoglobulin-containing substances&#xD;
&#xD;
               -  Concurrent participation of clinical trials of COVID-19 treatment&#xD;
&#xD;
               -  Possibility of transfer to other hospital within 72 hours&#xD;
&#xD;
               -  Heart Failure (NYHA Class III or higher) or other diseases with risks of volume&#xD;
                  overload&#xD;
&#xD;
               -  Permanent organ failure unrelated to COVID-19, including:&#xD;
&#xD;
                    -  End-stage liver disease (CTP score &gt;10 or MELD score &gt;40)&#xD;
&#xD;
                    -  End stage renal disease with creatinine clearance &lt;30% or in routine&#xD;
                       dialysis&#xD;
&#xD;
               -  Multiple organ failure (SOFA score ≥11)&#xD;
&#xD;
               -  Concomitant condition or treatment with risks of thrombosis, e.g.,&#xD;
                  cryoglobulinemia, refractory hypertriglyceridemia, or monoclonal gammopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Muljono, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eijkman Institute for Molecular Biology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irmansyah, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sri Idaiani, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tetra Fajarwati, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Karyana, MD, MKes</last_name>
    <phone>062816789813</phone>
    <email>mkaryana@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Retna M Indah, MD, MPH</last_name>
    <phone>0628990222987</phone>
    <email>retnaindah.sugiyono@ina-respond.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aceh Tamiang Hospital</name>
      <address>
        <city>Aceh Tamiang</city>
        <state>Aceh</state>
        <zip>13760</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wahyudin, MD,SpPD</last_name>
      <email>wahyuddin@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Andika Putra, MD,SpPD</last_name>
      <email>andikaputra_13@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wahyudin, MD,SpPD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andika Putra, MD,SpPD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hadjar Siswantoro, MD,MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanglah Central Hospital</name>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ni Wayan Candrawati, MD,SpP</last_name>
      <email>niwayancandrawati@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>I Ketut Agus Somia, MD,SpPD-KPTI</last_name>
      <email>agus.somia@unud.ac.id</email>
    </contact_backup>
    <investigator>
      <last_name>Ni Wayan Candrawati, MD,SpP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>I Ketut Agus Somia, MD,SpPD-KPTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Widianto Pancaharjono, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Udayana University Hospital</name>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I Wayan Aryabiantara, MD,SpAn-KIC</last_name>
      <email>aryabiantara@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Cokorda Agung W Purnamasidhi, MD</last_name>
      <email>purnamasidhi@unud.ac.id</email>
    </contact_backup>
    <investigator>
      <last_name>I Wayan Aryabiantara, MD,SpAn-KIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cokorda Agung W Purnamasidhi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Made A Lely Suratri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Soeradji Tirtonegoro Hospital</name>
      <address>
        <city>Klaten</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achmad Thabrani, MD,SpPD</last_name>
      <email>thabraniachmad0@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zakiah Novianti, MD,SpP</last_name>
      <email>zakiahnovianti.pulmonologist@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Achmad Thabrani, MD,SpPD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zakiah Novianti, MD,SpP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tince Jovina, drg,MKM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Wongsonegoro Regency Hospital</name>
      <address>
        <city>Semarang</city>
        <state>Central Java</state>
        <zip>50272</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny W Kandowangko, SpP</last_name>
      <email>kandowangko@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Diana Novitasari, SpPD,KEMD</last_name>
      <email>diana_budiharto@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jenny W Kandowangko, SpP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Novitasari, SpPD-KEMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lelly Andayasari, drg,MKes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasar Minggu Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Yanuar Fajar, MD,SpP</last_name>
      <email>mohyanfa_dr@yahoo.co.id</email>
    </contact>
    <contact_backup>
      <last_name>Sri Rachmawati, SpAn-KIC</last_name>
      <email>srirachmawati1945@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammad Yanuar Fajar, MD,SpP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sri Rachmawati, MD,SpAn-KIC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lelly Andayasari, drg,MKes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Haryoto Regency Hospital</name>
      <address>
        <city>Lumajang</city>
        <state>East Java</state>
        <zip>67311</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halimi Maksum, MD,MMRS</last_name>
      <email>halimi_maksum@yahoo.co.id</email>
    </contact>
    <contact_backup>
      <last_name>Dwi Yuliati, MD,SpP</last_name>
      <email>dyparu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Halimi Maksum, MD,MMRS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dwi Yuliati, MD,SpP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lusitawati, MSi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waluyo Jati Kraksaan Regency Hospital</name>
      <address>
        <city>Probolinggo</city>
        <state>East Java</state>
        <zip>67282</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yessi Rachmawati, MD,SpOG-K</last_name>
      <email>yessirahmawati76@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>M. Reza, MD,MSc,SpA</last_name>
      <email>reza.paed@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yessi Rachmawati, MD,SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Reza, MD,MSc,SpA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arvina Silalahi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidoarjo Regency Hospital</name>
      <address>
        <city>Sidoarjo</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nisvi Dewi Andaningrum,,SpPD</last_name>
      <email>nisvidewi22@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Raditya Rizky Muhammad, MD</last_name>
      <email>radityarizki25@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nisvi Dewi Andaningrum, MD,SpPD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raditya Rizky Muhammad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutfah Rif'ati, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr Ramelan Navy Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fransiscus OH Prasetyadi, MD,SpOG-K</last_name>
      <email>fransohp@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sri SI Marthaty, MD,SpP</last_name>
      <email>ss.indah.martha@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fransiscus OH Prasetyadi, MD,SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sri SI Marthaty, MD,SpP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sri M Nugraha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Soetomo Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bambang P Semadi, MD,SpAn-KIC</last_name>
      <email>bpsemedi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ugroseno Y Bintoro, MD,SpPD-KHOM</last_name>
      <email>ugrosenoyb2004@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bambang P Semadi, MD,SpAn-KIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ugroseno Y Bintoro, MD,SpPD-KHOM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Fajar Mogsa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital for COVID-19 - Wisma Atlet Kemayoran</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>14360</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Efriadi Ismail, MD,SpP(K)</last_name>
      <email>efriadidr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Arief Riadi Arifin, MD,SpP(K)</last_name>
      <email>riadiarifin4@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Efriadi Ismail, SpP(K)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arief Riadi Arifin, SpP(K)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tince Arniati Jovina, drg,MKM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. R.D. Kandou Hospital</name>
      <address>
        <city>Manado</city>
        <state>North Sulawesi</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda WA Rotty, SpPDKHOMProf</last_name>
      <email>linda_rotty@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>John Wantania, SpOG-K,Prof</last_name>
      <email>john_w_md@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Linda Rotty, SpPDKHOMProf</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Wantania, SpOG-K,Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Fajar Mogsa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Tadjuddin Chalid Hospital</name>
      <address>
        <city>Makassar</city>
        <state>Souh Sulawesi</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sitti Nursiyah, MD,SpP</last_name>
      <email>ichanurisyah@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Erwin Arief, MD,SpPD-KP</last_name>
      <email>erwin.pulmo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sitti Nursiyah, MD,SpP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erwin Arief, MD,SpPD-KP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tince Jovina, Drg, MKM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Wahidin Sudirohusodo Central Hospital</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <zip>90245</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Muchtar, MD,SpAn-KIC</last_name>
      <email>faisal_kedok@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Andi Adil, MD,SpAn-KAKV</last_name>
      <email>adilzanetti4444@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Faisal Muchtar, MD,SpAn-KIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andi Adil, MD,SpAn-KAKV</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sundari Wirasmi, SSi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hasanuddin University Hospital</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <zip>90245</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haizah Nurdin, MD,SpAn-KIC</last_name>
      <email>haizahnurdin.anestesi@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Rezki Hardiyanti, SpAn</last_name>
      <email>rezkihardiyanti.taufik@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Haizah Nurdin, MD,SpAn-KIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rezki Hardiyanti, SpAn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lusitawati, MSi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dadi Hospital</name>
      <address>
        <city>Makassar</city>
        <state>South Sulawesi</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alamsyah AA Husain, M</last_name>
      <email>alamsyah.md@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Muhammad Iswan Wahab, MD</last_name>
      <email>iswanwahab@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alamsyah AA Husain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammad Iswan Wahab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arvina Silalahi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Mohammad Hoesin Central Hospital</name>
      <address>
        <city>Palembang</city>
        <state>South Sumatra</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zen Achmad, MD,SpPD-KP</last_name>
      <email>joniahmad21@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Nelda Aprilia Salim, MD,SpPD</last_name>
      <email>apriliadoctor@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zen Achmad, MD,SpPD-KP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelda Aprilia Salim, MD,SpPD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Widianto Pancaharjono, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Hasan Sadikin Central Hospital</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruswana Anwar, OG(REI),PhD</last_name>
      <email>ruswana_anwar@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Dimmy Prasetya, MD,SpPD-KHOM</last_name>
      <email>dimmyprasetyaipd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ruswana Anwar, OG(REI),PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimmy Prasetya, MD,SpPD-KHOM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutfah Rif'ati, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RSD Gunung Jati</name>
      <address>
        <city>Cirebon</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agung Hujjatulislam, MD,SpAn,KIC</last_name>
      <email>agung.hujjatulislam@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Oom Nurrohmah, MD,SpPD</last_name>
      <email>oomnurrohmah2@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Agung Hujjatulislam, MD,SpAn,KIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oom Nurrohmah, MD,SpPD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christa G. Manik, SKep,NS,MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gatot Soebroto Central Army Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Retno Wihastuti, MD,SpP</last_name>
      <email>rwihastuti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marliana S Rejeki, MD,SpFK</last_name>
      <email>marliana.sr@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Retno Wihastuti, MD,SpP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marliana S Rejeki, MD,SpFK</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Made A Lely Suratri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>dr. Cipto Mangunkusumo National Central General Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cleopas Martin Rumende, MD,SpPD-KP</last_name>
      <email>rumende_martin@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Cleopas Martin Rumende, MD,SpPD-KP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lugyanti Sukrisman, MD,SpPD,KHOM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nova Sri Hartati, MD,MGizi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>YARSI Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>10510</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faizal Drissa Hasibuan, SpPD-KHOM</last_name>
    </contact>
    <investigator>
      <last_name>Faizal Drissa Hasibuan, SpPD-KHOM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rika Bur, SpPD-KPTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annisa Rizky Afrilia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Suyoto Pusrehab Kemenhan Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>12330</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eko Martdiyanto, MD,SpP</last_name>
      <email>drechom@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Arditya Endiarsari, MD,SpPK</last_name>
      <email>arditya.endiarsari@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eko Martdiyanto, MD,SpP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arditya Endiarsari, MD,SpPK</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annisa Rizky Afrilia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Persahabatan Central hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>13230</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sita Laksmi Andarini, MD,SpP-KP</last_name>
      <email>sitaandarini@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sita Laksmi Andarini, MD,SpP-KP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hayatun Nufus, MD,SpPD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lelly Andayasari, drg,MKes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fatmawati Central Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Iskandar, MD,SpPD</last_name>
      <email>marthaiskandar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Krishna A Wibisana, MD,SpPD</last_name>
      <email>K.wibisana@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martha Iskandar, MD,SpPD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krishna A Wibisana, MD,SpPD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aprildah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Sulianti Saroso Infectious Disease Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herlina, MD,SpPD</last_name>
      <email>herlinadr21@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dian Wahyu W Tanjungsari, MD,SpPK</last_name>
      <email>dianwahyu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Herlina, MD,SpPD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dian Wahyu Tanjungsari, MD,SpPK</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sundari Wirasmi, SSi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Indonesia Hospital (RSUI)</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>Coronavirus Disease 2019 (COVID-19) Treatment Guidelines</description>
  </link>
  <link>
    <url>https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-applications-inds-cber-regulated-products/recommendations-investigational-covid-19-convalescent-plasma</url>
    <description>Recommendations for Investigational COVID-19 Convalescent Plasma</description>
  </link>
  <link>
    <url>https://www.medrxiv.org/content/10.1101/2020.07.01.20139857v1</url>
    <description>Convalescent Plasma for COVID-19. A randomized clinical trial</description>
  </link>
  <link>
    <url>https://www.who.int/publications/i/item/clinical-management-of-covid-19/</url>
    <description>Clinical management of COVID-19: Interim guidance</description>
  </link>
  <link>
    <url>https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf</url>
    <description>WHO R &amp; D. COVID-19 Therapeutic Trial Synopsis</description>
  </link>
  <link>
    <url>https://evs.nci.nih.gov/ftp1/CTCAE/About.html</url>
    <description>NCI Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </link>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <reference>
    <citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. Review.</citation>
    <PMID>25030060</PMID>
  </reference>
  <reference>
    <citation>Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044. Erratum in: JAMA. 2020 Aug 4;324(5):519.</citation>
    <PMID>32492084</PMID>
  </reference>
  <reference>
    <citation>Szakó L, Farkas N, Kiss S, Váncsa S, Zádori N, Vörhendi N, Erőss B, Hegyi P, Alizadeh H. Convalescent plasma therapy for COVID-19 patients: a protocol of a prospective meta-analysis of randomized controlled trials. Trials. 2021 Feb 1;22(1):112. doi: 10.1186/s13063-021-05066-2.</citation>
    <PMID>33522939</PMID>
  </reference>
  <reference>
    <citation>Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev. 2020 Aug 12;33(4). pii: e00072-20. doi: 10.1128/CMR.00072-20. Print 2020 Sep 16. Review.</citation>
    <PMID>32792417</PMID>
  </reference>
  <reference>
    <citation>Diago-Sempere E, Bueno JL, Sancho-López A, Rubio EM, Torres F, de Molina RM, Fernández-Cruz A, de Diego IS, Velasco-Iglesias A, Payares-Herrera C, Flecha IC, Avendaño-Solà C, Palomino RD, Ramos-Martínez A, Ruiz-Antorán B. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials. 2021 Jan 20;22(1):70. doi: 10.1186/s13063-020-05011-9.</citation>
    <PMID>33472681</PMID>
  </reference>
  <reference>
    <citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12. Review. Erratum in: Lancet Infect Dis. 2020 Oct;20(10):e250.</citation>
    <PMID>32539990</PMID>
  </reference>
  <reference>
    <citation>Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.</citation>
    <PMID>32362390</PMID>
  </reference>
  <reference>
    <citation>Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. Radiol Med. 2020 May;125(5):509-513. doi: 10.1007/s11547-020-01200-3. Epub 2020 May 1.</citation>
    <PMID>32358689</PMID>
  </reference>
  <reference>
    <citation>Ekmekci PE, Arda B. Interculturalism and Informed Consent: Respecting Cultural Differences without Breaching Human Rights. Cultura (Iasi). 2017;14(2):159-172.</citation>
    <PMID>29645014</PMID>
  </reference>
  <reference>
    <citation>Zulu JM, Sandøy IF, Moland KM, Musonda P, Munsaka E, Blystad A. The challenge of community engagement and informed consent in rural Zambia: an example from a pilot study. BMC Med Ethics. 2019 Jul 4;20(1):45. doi: 10.1186/s12910-019-0382-x.</citation>
    <PMID>31272489</PMID>
  </reference>
  <reference>
    <citation>Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021 Mar 23;325(12):1185-1195. doi: 10.1001/jama.2021.2747.</citation>
    <PMID>33635310</PMID>
  </reference>
  <reference>
    <citation>Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M, Rondan A, Lescano G, Cruz P, Ritou Y, Fernández Viña V, Álvarez Paggi D, Esperante S, Ferreti A, Ofman G, Ciganda Á, Rodriguez R, Lantos J, Valentini R, Itcovici N, Hintze A, Oyarvide ML, Etchegaray C, Neira A, Name I, Alfonso J, López Castelo R, Caruso G, Rapelius S, Alvez F, Etchenique F, Dimase F, Alvarez D, Aranda SS, Sánchez Yanotti C, De Luca J, Jares Baglivo S, Laudanno S, Nowogrodzki F, Larrea R, Silveyra M, Leberzstein G, Debonis A, Molinos J, González M, Perez E, Kreplak N, Pastor Argüello S, Gibbons L, Althabe F, Bergel E, Polack FP; Fundación INFANT-COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.</citation>
    <PMID>33406353</PMID>
  </reference>
  <reference>
    <citation>Marx R, Eggert G, Beldner W. [Thermal expansion and plasticizing temperatures of dental adhesives]. Dtsch Zahnarztl Z. 1988 Apr;43(4):465-8. German.</citation>
    <PMID>3044747</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009 Jan;32 Suppl 1:S62-7. doi: 10.2337/dc09-S062.</citation>
    <PMID>19118289</PMID>
  </reference>
  <reference>
    <citation>Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009 May;37(5):1649-54. doi: 10.1097/CCM.0b013e31819def97.</citation>
    <PMID>19325482</PMID>
  </reference>
  <reference>
    <citation>Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6.</citation>
    <PMID>12512033</PMID>
  </reference>
  <reference>
    <citation>Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89. Review.</citation>
    <PMID>16305721</PMID>
  </reference>
  <reference>
    <citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.</citation>
    <PMID>23747642</PMID>
  </reference>
  <reference>
    <citation>Ng JJ, Luo Y, Phua K, Choong AMTL. Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): A meta-analysis. J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.05.009. Epub 2020 May 8.</citation>
    <PMID>32389782</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Moderate</keyword>
  <keyword>Severe</keyword>
  <keyword>Convalescent Plasma</keyword>
  <keyword>Indonesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The original datasets used for this study are not publicly available due to the existing regulation, and only can be shared upon the approval of the Sponsor on behalf of the Ministry of Health.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>January 1 - December 31, 2021</ipd_time_frame>
    <ipd_access_criteria>The study protocol and and raw data are only shared to the ClinicalTrials.gov and/or Journal Reviewers.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

